ApoB: The Cardiovascular Marker Your Doctor Probably Missed

Your doctor looks at your LDL cholesterol and says it's fine. 110 mg/dL. Below the 130 threshold. No statin needed.

Your ApoB, if your doctor had ordered it, might be 95 mg/dL — elevated enough that the Multi-Ethnic Study of Atherosclerosis would put you in a higher-risk tertile for coronary artery disease. The difference matters because two men with identical LDL-C can have very different ApoB values, and it's the ApoB — the actual particle count — that drives atherosclerosis.

ApoB isn't a fringe test. The European Atherosclerosis Society considers it the preferred primary lipid marker. The American Heart Association guidelines include it. And yet, in American primary care in 2026, most men have never had it measured.

The Basic Biology

Every atherogenic lipoprotein particle in your blood — LDL, VLDL, IDL, lipoprotein(a) — carries exactly one apolipoprotein B-100 molecule on its surface. ApoB is the structural backbone of these particles. Count ApoB and you have counted, directly, the particles capable of entering your artery wall and contributing to plaque formation.

LDL cholesterol (LDL-C) measures the cholesterol mass inside those particles, not the particles themselves. Two particles with half the cholesterol produce the same LDL-C as one particle with full cholesterol — but two particles are twice as likely to drive atherosclerosis.

This is why ApoB correlates more tightly with cardiovascular events than LDL-C in essentially every large study that has measured both.

The Discordance Problem

"Discordance" is the clinical term for when LDL-C and ApoB tell different stories. It happens in roughly 15-25% of patients, particularly those with:

• Insulin resistance or metabolic syndrome
• Small dense LDL particles (common in apo-B-high, triglyceride-high patterns)
• Type 2 diabetes
• Genetic lipid disorders

The characteristic pattern: "normal" LDL-C but elevated ApoB, indicating many small dense particles rather than few large fluffy ones. Small dense LDL is more atherogenic per particle than large buoyant LDL. A patient with this pattern looks fine on standard lipids and has substantially elevated risk.

The reverse discordance — LDL-C looks high but ApoB is normal — is less common but exists, particularly in some genetic variants. These patients might be prescribed statins unnecessarily on LDL-C alone.

Optimal ApoB Targets

Targets depend on risk stratification. Broadly:

• Very high risk (prior cardiovascular events, diabetes with complications): under 65 mg/dL
• High risk (diabetes, Lp(a) elevated, family history, multiple risk factors): under 80 mg/dL
• Moderate risk (some risk factors): under 90 mg/dL
• Low risk (young, no risk factors): under 100 mg/dL

The "lower is better" principle applies broadly. The Mendelian randomization data on ApoB is compelling: genetic variants that produce lifelong low ApoB levels are associated with dramatically reduced cardiovascular risk, even at values well below conventional targets. Pushing ApoB toward 60 mg/dL in high-risk patients appears safe and beneficial.

Getting Tested

ApoB is a standard assay offered by all major labs. CPT code 82172. Direct-to-consumer typically $30-80. Through insurance with physician order, usually covered.

Fasting not strictly required, but a 9-12 hour fast reduces variability and makes the test interpretable alongside a full lipid panel. Draw first thing in the morning.

One measurement gives you a usable number. Retest annually or after interventions.

What Raises ApoB

Genetic factors contribute substantially — some people produce more atherogenic particles at any level of lifestyle. Beyond genetics:

• Saturated fat intake (the single biggest dietary lever, though effect size varies by individual)
• Trans fats (still present in some processed foods despite regulations)
• Refined carbohydrates (elevate triglycerides and VLDL, contributing to small dense LDL pattern)
• Alcohol (raises VLDL)
• Visceral adiposity
• Insulin resistance
• Hypothyroidism
• Certain medications (beta-blockers, corticosteroids, some antipsychotics)

What Lowers ApoB

Statins: The most robust intervention. Typical statins reduce ApoB by 30-50% depending on dose and drug. Atorvastatin 40 mg or rosuvastatin 20 mg provides substantial reduction with good safety profile.

Ezetimibe: Additional 15-20% reduction when added to statins. Well-tolerated, inexpensive.

PCSK9 inhibitors: Additional 50-60% reduction in ApoB, via injections every 2-4 weeks. Expensive but transformative for high-risk patients.

Bempedoic acid: Oral, modest reduction (15-25%), useful for statin-intolerant patients.

Dietary interventions:

• Reducing saturated fat to below 6% of calories: 10-15% ApoB reduction typically
• Increasing soluble fiber to 10-25 g daily: 5-10% reduction
• Plant sterols and stanols (fortified foods, supplements): 5-10% reduction
• Replacing refined carbs with whole foods: modest effect via VLDL reduction

Weight loss: 10-15% body weight reduction typically reduces ApoB 10-15% through multiple mechanisms.

Exercise: Modest direct effect; larger indirect effect via weight and insulin sensitivity.

The Statin Question for Men with Elevated ApoB

This is where discussion gets contentious among patients. Statins work — the Mendelian data, the randomized trials, and the pharmacoepidemiology all agree. They reduce cardiovascular events substantially.

Side effect rate is lower than Internet discourse suggests. Muscle pain occurs in roughly 5-10% of users in blinded trials (vs 1-3% on placebo — so statin-specific muscle pain is real but less common than often claimed). Serious muscle damage (rhabdomyolysis) is rare — roughly 0.01-0.1% annually.

Diabetes risk from statins is real but small — a 9% increased relative risk. In a patient at meaningful cardiovascular risk, this is usually worth the trade.

Cognitive effects: trials don't show consistent evidence. Individual reports exist.

For a man with elevated ApoB (above 100 mg/dL) and additional risk factors, statin therapy is strongly evidence-based. For a man with isolated mildly elevated ApoB and no other risk factors, lifestyle first is reasonable. For a man with elevated ApoB plus elevated Lp(a), family history, or diabetes, aggressive treatment is justified.

The conversation should be with a doctor who understands lipidology — ideally a cardiologist or lipidologist for complex cases, not primary care alone if the picture is nuanced.

The Carbohydrate-Fat Question

Low-carb and keto diets often raise LDL-C and ApoB in a subset of responders ("lean mass hyper-responders"), particularly those who are lean and insulin-sensitive. Whether this matters for cardiovascular risk is contested.

The practical answer: if you're on low-carb and your ApoB rises significantly, don't dismiss it. Test. If elevated, consider adjustments — more monounsaturated fats (olive oil, nuts), less saturated fat, possibly medication depending on overall risk profile. Don't assume "it's different with keto" without data.

The Takeaway

If your cardiovascular assessment has been LDL-C alone, you've been getting partial information. Request ApoB at your next blood draw. If it's elevated, understand that your cardiovascular risk is higher than your LDL-C suggests. Talk to your doctor about how the number changes your risk picture and what treatment options make sense in your specific case.

For men over 35 tracking their own cardiovascular trajectory, ApoB should be on the annual panel without exception. It's the single most informative lipid number and one of the cheapest interventions to access.